Rain Enhancement Technologies Holdco (RAIN)
Market Price (3/30/2026): $2.79 | Market Cap: $21.2 MilSector: Industrials | Industry: Environmental & Facilities Services
Rain Enhancement Technologies Holdco (RAIN)
Market Price (3/30/2026): $2.79Market Cap: $21.2 MilSector: IndustrialsIndustry: Environmental & Facilities Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Climate Adaptation & Resilience. Themes include Atmospheric Water Management, and Water Security Solutions. | Weak multi-year price returns2Y Excs Rtn is -84%, 3Y Excs Rtn is -124% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -5.2 Mil | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -32% | ||
| High stock price volatilityVol 12M is 129% |
| Megatrend and thematic driversMegatrends include Climate Adaptation & Resilience. Themes include Atmospheric Water Management, and Water Security Solutions. |
| Weak multi-year price returns2Y Excs Rtn is -84%, 3Y Excs Rtn is -124% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -5.2 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -32% |
| High stock price volatilityVol 12M is 129% |
Qualitative Assessment
AI Analysis | Feedback
1. Nasdaq Listing Deficiency due to Low Market Value.
Rain Enhancement Technologies Holdco, Inc. received a notice from Nasdaq on February 20, 2026, indicating that its market value of listed securities had closed below the $35 million minimum required for continued listing for 30 consecutive business days. As of March 20, 2026, the company's market capitalization was approximately $24.81 million to $24.82 million, a significant shortfall from the Nasdaq requirement. This deficiency raises concerns about the company's ability to maintain its listing and negatively impacts investor confidence.
2. Poor Financial Health and Significant Cash Burn.
The company exhibits weak financial health, characterized by a rapid depletion of cash reserves. An InvestingPro analysis as of February 20, 2026, assigned a "WEAK" Financial Health score of 0.77 and noted that the company is "quickly burning through cash". This ongoing cash consumption indicates underlying operational and financial instability, contributing to the stock's decline.
Show more
Stock Movement Drivers
Fundamental Drivers
The -49.1% change in RAIN stock from 11/30/2025 to 3/29/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.40 | 2.75 | -49.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 8 | 8 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| RAIN | -49.1% | |
| Market (SPY) | -5.3% | 8.2% |
| Sector (XLI) | 3.9% | 7.1% |
Fundamental Drivers
The -28.6% change in RAIN stock from 8/31/2025 to 3/29/2026 was primarily driven by a -9.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.85 | 2.75 | -28.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 7 | 8 | -9.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| RAIN | -28.6% | |
| Market (SPY) | 0.6% | 18.1% |
| Sector (XLI) | 5.5% | 11.3% |
Fundamental Drivers
The 19.6% change in RAIN stock from 2/28/2025 to 3/29/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.30 | 2.75 | 19.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 0 | 0.0% |
| P/S Multiple | � | ∞ | 0.0% |
| Shares Outstanding (Mil) | 7 | 8 | -9.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| RAIN | 19.6% | |
| Market (SPY) | 9.8% | 11.5% |
| Sector (XLI) | 18.4% | 11.0% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| RAIN | ||
| Market (SPY) | 69.4% | 6.3% |
| Sector (XLI) | 65.1% | 6.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RAIN Return | - | - | - | - | -20% | -51% | -61% |
| Peers Return | 37% | -15% | 22% | 11% | 9% | -6% | 61% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| RAIN Win Rate | - | - | - | - | 50% | 67% | |
| Peers Win Rate | 65% | 42% | 55% | 55% | 63% | 47% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| RAIN Max Drawdown | - | - | - | - | -75% | -63% | |
| Peers Max Drawdown | -4% | -35% | -13% | -9% | -17% | -8% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: XYL, PNR, WTS, TTEK, LNN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
RAIN has limited trading history. Below is the Industrials sector ETF (XLI) in its place.
| Event | XLI | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -22.6% | -25.4% |
| % Gain to Breakeven | 29.2% | 34.1% |
| Time to Breakeven | 273 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -42.8% | -33.9% |
| % Gain to Breakeven | 74.8% | 51.3% |
| Time to Breakeven | 232 days | 148 days |
| 2018 Correction | ||
| % Loss | -24.6% | -19.8% |
| % Gain to Breakeven | 32.6% | 24.7% |
| Time to Breakeven | 312 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -63.3% | -56.8% |
| % Gain to Breakeven | 172.8% | 131.3% |
| Time to Breakeven | 1,463 days | 1,480 days |
Compare to XYL, PNR, WTS, TTEK, LNN
In The Past
SPDR Select Sector Fund's stock fell -22.6% during the 2022 Inflation Shock from a high on 1/4/2022. A -22.6% loss requires a 29.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Rain Enhancement Technologies Holdco (RAIN)
AI Analysis | Feedback
It's like an early-stage **Gilead Sciences** or **Vertex Pharmaceuticals**, but solely focused on developing new cancer therapies.
Think of it as a specialized **Amgen** or **Roche** that is still in the process of bringing its first major cancer drugs to market through clinical trials.
AI Analysis | Feedback
- Milademetan: A small molecule oral inhibitor of mouse double minute 2 (MDM2) that is being developed for various cancers, including liposarcoma, solid tumors, and intimal sarcoma.
- RAD52: A preclinical-stage drug candidate being investigated for its potential in treating a range of tumors, such as breast, ovarian, pancreatic, and prostate cancers.
AI Analysis | Feedback
Based on the provided background description, Rain Therapeutics Inc. (symbol: RAIN) is a clinical-stage precision oncology company. Its primary focus is on the development of therapies that target oncogenic drivers, such as milademetan and RAD52, which are currently in various phases of clinical trials (Phase 3, Phase II, and preclinical stages).
As a company in the clinical development stage, Rain Therapeutics Inc. does not currently have major customers in the traditional sense, as its product candidates have not yet received regulatory approval for commercial sale. Therefore, it does not sell its therapies to other companies or directly to individuals at this time.
If its product candidates are successfully developed and approved, future 'customers' would likely include healthcare providers, hospitals, and potentially pharmacies, who would then administer or dispense the therapies to patients.
AI Analysis | Feedback
nullAI Analysis | Feedback
Randy Seidl
Chief Executive Officer and Director
Randy Seidl serves as the Chief Executive Officer and Director of Rain Oncology Inc..
Oanh Truong
Interim Chief Financial Officer
Oanh Truong is the Interim Chief Financial Officer of Rain Oncology Inc..
Robert C. Doebele M.D., Ph.D.
President, Chief Scientific Officer & Co-Founder
Dr. Robert C. Doebele is a Co-Founder, President, and Chief Scientific Officer of Rain Oncology Inc.. He co-founded Rain Therapeutics Inc. (now Rain Oncology Inc.) in April 2017. Dr. Doebele's expertise in precision oncology is central to shaping the company's corporate strategy and advancing its clinical pipeline and research and development efforts.
Richard P. Bryce MBChB, MFPM, MRCGP
Executive VP & Chief Medical Officer
Dr. Richard P. Bryce serves as the Executive Vice President and Chief Medical Officer. He joined Rain with over 30 years of experience in oncology, clinical research, and biopharmaceutical roles. Previously, he was Chief Medical and Scientific Officer at Puma Biotechnology, where he led the development of neratinib through FDA approval for breast cancer. His prior experience also includes senior medical director roles at Onyx Pharmaceuticals and various clinical and medical leadership positions at ICON Clinical Research, Ergomed Clinical Research, F. Hoffmann-La Roche, ILEX Oncology, Scotia Pharmaceuticals, and Servier Laboratories.
Vijaya Tirunagaru Ph.D.
Senior VP & Head of Research
Dr. Vijaya Tirunagaru is the Senior Vice President and Head of Research for Rain Oncology Inc.. She has contributed to the presentation of preclinical data for milademetan in MDM2-amplified tumors.
AI Analysis | Feedback
nullAI Analysis | Feedback
null
AI Analysis | Feedback
Rain Therapeutics Inc., a clinical-stage precision oncology company, focuses on developing therapies for various cancers. The addressable markets for its main products and services are detailed below:
Milademetan (MDM2 Inhibitor)
- Liposarcoma: Approximately 1,000 new cases of dedifferentiated liposarcoma (DDLPS) are estimated to occur in the U.S. annually. The global sarcoma drugs market, which includes liposarcoma, was valued at USD 2.1 billion in 2025 and is projected to reach USD 4.6 billion by 2035.
- Intimal Sarcoma: While specific market size data for intimal sarcoma is not readily available, it falls under the broader category of sarcomas. The global sarcoma drugs market was valued at USD 2.1 billion in 2025 and is predicted to reach USD 4.6 billion by 2035.
- Solid Tumors: Milademetan is also in Phase II clinical trials for solid tumors. Although there are currently no FDA-approved MDM2 inhibitors on the market, various MDM2 inhibitors are under investigation for their efficacy in solid tumors. The global protein inhibitors market, which may include MDM2 inhibitors, is estimated at USD 50 billion in 2025 and is projected to reach approximately USD 95 billion by 2033. The global cell cycle inhibitors market, which involves MDM2, was valued at USD 9.84 billion in 2024 and is projected to reach USD 21.71 billion by 2032.
RAD52 (DNA Repair Pathway Target)
- Global DNA Repair Drugs Market: The global DNA repair drugs market is projected to grow from USD 5.6 billion in 2024 to USD 10.7 billion by 2030.
- Breast Cancer: The global breast cancer therapeutics market was estimated at USD 31.5 billion in 2024 and is expected to grow to USD 71.3 billion by 2034. The U.S. breast cancer therapeutics market accounted for USD 11.9 billion in 2024.
- Ovarian Cancer: The global ovarian cancer drugs market size was valued at USD 3.5 billion in 2023 and is expected to reach USD 6.1 billion by 2032. The U.S. ovarian cancer drugs market size is estimated at USD 1.30 billion in 2025 and is projected to be around USD 2.57 billion by 2035.
- Pancreatic Cancer: The global pancreatic cancer treatment market was valued at USD 3 billion in 2023 and is anticipated to witness growth at a CAGR of 13.2% over the analysis period. Another estimate projects the global market size at USD 4.3 billion in 2026, reaching USD 12.6 billion by 2033, with North America expected to account for 38% of this market.
- Prostate Cancer: The global prostate cancer therapeutics market was valued at USD 12.6 billion in 2024 and is projected to reach USD 29.9 billion by 2034. North America accounted for 39.2% of the global market in 2024. The U.S. market was valued at USD 3.7 billion in 2021.
AI Analysis | Feedback
NullAI Analysis | Feedback
Share Issuance
- Rain Enhancement Technologies Holdco's shares outstanding were tracked from 2022 to 2025.
- As of March 13, 2026, the company had approximately 8.18 million total shares outstanding.
- As of September 30, 2025, Rain Enhancement Technologies Holdco had 8.19 million shares outstanding.
Capital Expenditures
- Rain Enhancement Technologies Holdco allocates capital towards developing, manufacturing, and commercializing its ionization rainfall generation technology.
- The focus of these expenditures includes improvements on existing rainfall generation technologies by introducing robust measurement tools, such as software monitoring technology, machine learning, rain gauges, and weather stations.
- A core area of investment is ionization-based cloud seeding technology to address global water scarcity.
Trade Ideas
Select ideas related to RAIN.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02272026 | EFX | Equifax | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | LZ | LegalZoom.com | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 7.2% | 7.2% | -5.0% |
| 02132026 | ADP | Automatic Data Processing | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 1.1% | 1.1% | -3.0% |
| 02132026 | TREX | Trex | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | -3.2% | -3.2% | -5.9% |
| 02132026 | PCTY | Paylocity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -0.6% | -0.6% | -4.8% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 101.23 |
| Mkt Cap | 8.7 |
| Rev LTM | 3,307 |
| Op Inc LTM | 536 |
| FCF LTM | 427 |
| FCF 3Y Avg | 390 |
| CFO LTM | 459 |
| CFO 3Y Avg | 411 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.5% |
| Rev Chg 3Y Avg | 7.2% |
| Rev Chg Q | 4.9% |
| QoQ Delta Rev Chg LTM | 1.2% |
| Op Mgn LTM | 14.7% |
| Op Mgn 3Y Avg | 13.5% |
| QoQ Delta Op Mgn LTM | 0.4% |
| CFO/Rev LTM | 16.5% |
| CFO/Rev 3Y Avg | 15.9% |
| FCF/Rev LTM | 10.1% |
| FCF/Rev 3Y Avg | 12.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 8.7 |
| P/S | 3.2 |
| P/EBIT | 15.5 |
| P/E | 21.6 |
| P/CFO | 16.0 |
| Total Yield | 5.0% |
| Dividend Yield | 1.0% |
| FCF Yield 3Y Avg | 4.2% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -12.6% |
| 3M Rtn | -13.7% |
| 6M Rtn | -16.3% |
| 12M Rtn | 1.3% |
| 3Y Rtn | 11.5% |
| 1M Excs Rtn | -4.8% |
| 3M Excs Rtn | -5.7% |
| 6M Excs Rtn | -11.7% |
| 12M Excs Rtn | -12.0% |
| 3Y Excs Rtn | -45.8% |
Price Behavior
| Market Price | $2.75 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 04/23/2021 | |
| Distance from 52W High | -66.2% | |
| 50 Days | 200 Days | |
| DMA Price | $2.75 | $3.30 |
| DMA Trend | down | down |
| Distance from DMA | 0.0% | -16.7% |
| 3M | 1YR | |
| Volatility | 115.4% | 131.0% |
| Downside Capture | 1.53 | 0.82 |
| Upside Capture | -213.77 | 129.72 |
| Correlation (SPY) | 1.1% | 12.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.42 | -0.20 | 0.53 | 1.92 | 0.69 | 1.03 |
| Up Beta | -6.99 | -2.53 | -1.38 | 0.21 | 1.08 | -0.87 |
| Down Beta | -3.25 | 1.31 | 1.15 | 1.64 | -0.06 | -0.69 |
| Up Capture | 146% | -380% | -139% | 183% | 63% | -2% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 9 | 14 | 25 | 55 | 114 | 124 |
| Down Capture | 261% | 392% | 270% | 239% | 92% | 55% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 12 | 27 | 36 | 68 | 129 | 156 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RAIN | |
|---|---|---|---|---|
| RAIN | 22.5% | 130.3% | 0.77 | - |
| Sector ETF (XLI) | 20.5% | 19.2% | 0.84 | 13.3% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 13.4% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 1.7% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | -0.1% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 17.6% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 10.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RAIN | |
|---|---|---|---|---|
| RAIN | -19.4% | 126.7% | -0.12 | - |
| Sector ETF (XLI) | 12.3% | 17.2% | 0.56 | 7.4% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 6.7% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 1.6% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | -0.2% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 10.4% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 8.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RAIN | |
|---|---|---|---|---|
| RAIN | -10.2% | 126.7% | -0.12 | - |
| Sector ETF (XLI) | 13.0% | 19.8% | 0.58 | 7.4% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 6.7% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 1.6% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | -0.2% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 10.4% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 8.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dickerson, Lyman B | Direct | Sell | 9172025 | 5.24 | 1,917 | 10,045 | 81,990 | Form | |
| 2 | Dickerson, Lyman B | Direct | Sell | 9172025 | 5.55 | 215 | 1,193 | 85,648 | Form | |
| 3 | Dickerson, Lyman B | Direct | Sell | 9172025 | 5.80 | 398 | 2,308 | 87,197 | Form | |
| 4 | Dickerson, Lyman B | Direct | Sell | 9172025 | 5.78 | 4,787 | 27,669 | 59,228 | Form | |
| 5 | Dacier, Paul T | Direct | Buy | 2102025 | 11.39 | 13,173 | 150,040 | 150,040 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.